| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
This chapter of New Drug Futures evaluates, compares and contrasts the
prospects for the compounds that will revolutionise the pharmaceutical
industry over the next 5 years and beyond in the alimentary/metabolic sector.
The report includes unique sales forecasts by major product.
The full 400-page report, evaluates, compares and contrasts the prospects for
the compounds that will revolutionise the pharmaceutical industry over the
next 5 years and beyond. The report covers 8 key therapy areas
(alimentary/metabolic, anti-infectives, cancer, cardiovascular, CNS,
musculoskeletal, respiratory, vaccines) and includes unique sales forecasts by
major product. Click here for more information. This chapter is available
separately.
The alimentary/metabolic market is the third largest therapeutic category by
sales and generated nearly US$51.3bn (+4% YoY) in 2005. This market spans the
sale of a broad range of drugs including; anti-ulcerants (around 34%), drugs
for the treatment of gastro-oesophageal reflux disease, anti-diabetics (around
23% of the market) and anti-obesity drugs (around 2%). Sales grew slowly
throughout the world with over 50% derived in the US, 25% in Europe and 16% in
Japan.
TABLE OF CONTENTS
CURRENT MARKET SIZE
- ANTI-ULCERANT MARKET
- DIABETES MARKET
- OBESITY MARKET
ADDRESSABLE PATIENT POPULATION
- GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
- DIABETES
- OBESITY
CURRENT TREATMENTS
- TREATMENT OF GORD
- TREATMENT OF DIABETES
- TREATMENT OF DIABETIC NEUROPATHIES
- TREATMENT OF OBESITY
SALES DRIVERS
- ANTI-ULCERANT SALES DRIVERS
- ANTI-DIABETIC SALES DRIVERS
- ANTI-OBESITY SALES DRIVERS
SALES BREAKERS
- ANTI-ULCERANT SALES BREAKERS
- ANTI-DIABETIC SALES BREAKERS
- ANTI-OBESITY SALES BREAKERS
- FUTURE TREATMENTS
- MARKET DYNAMICS - WINNERS & LOSERS
KEY DRUGS LAUNCHES BY 2010
KEY EVALUATION CRITERIA
KEY ALIMENTARY / METABOLIC DRUG LAUNCHES BY 2010
- Acomplia (sanofi-aventis)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- STRATUS - Smoking cessation
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- AERx iDMS (NovoNordisk/Paradigm)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Arxxant (Eli Lilly)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- APD356 (Arena Pharmaceuticals)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- AVE-0010 (sanofi-aventis)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Byetta (Eli Lilly/Amylin)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Exubera (Pfizer)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Galida (AstraZeneca)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Galvus (Novartis)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Januvia (Merck & Co.)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Liraglutide (Novo Nordisk)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Competitor Ratio Analysis
- Naveglitazar (Eli Lilly)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Pargluva (BMS)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Saxagliptin- Metabolism (Bristol-Myers Squibb)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Soraprazan (Altana)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- Suloxdexide (Keryx)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
- TAK-390MR (Takeda)
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace/gaining share of voice
- Risks associated with developing a drug within a therapeutic class
- Filings and approval
- Sales forecasts and assumptions
- Competitor Ratio Analysis
COMPETITOR RATIO ANALYSIS SUMMARY
COMPETITOR RATIO ANALYSIS - DRUGS
COMPETITOR RATIO ANALYSIS - COMPANIES
|
